Immunocore (IMCR) Stock Forecast & Price Target

$32.42 -0.14 (-0.43%)

(As of 11/20/2024 ET)

Immunocore - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
1

Hold
3

Buy
9

Based on 13 Wall Street analysts who have issued ratings for Immunocore in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a sell rating, 3 have given a hold rating, and 9 have given a buy rating for IMCR.

Consensus Price Target

$69.18
113.39% Upside

According to the 13 analysts' twelve-month price targets for Immunocore, the average price target is $69.18. The highest price target for IMCR is $100.00, while the lowest price target for IMCR is $24.00. The average price target represents a forecasted upside of 113.39% from the current price of $32.42.

Get the Latest News and Ratings for IMCR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Immunocore and its competitors.

IMCR Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	11 Buy rating(s)	11 Buy rating(s)	14 Buy rating(s)
Hold	3 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$69.18	$79.82	$80.70	$75.00
Forecasted Upside	113.39% Upside	139.62% Upside	125.67% Upside	64.22% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

📉 Warning: Market Crash Predicted - Secure Your Savings (Ad)

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>

IMCR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IMCR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Immunocore Stock vs. The Competition

Type	Immunocore	Medical Companies	S&P 500
Consensus Rating Score	2.62	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	113.39% Upside	26,931.60% Upside	9.83% Upside
News Sentiment Rating	Positive News See Recent IMCR News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/11/2024	Mizuho 2 of 5 stars	G. Suvannavejh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$72.00 ➝ $38.00	+9.54%
11/7/2024	Needham & Company LLC 2 of 5 stars		Lower Target	Buy ➝ Buy	$78.00 ➝ $71.00	+111.88%
10/24/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00	+212.30%
10/24/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Dai Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$24.00	-25.05%
10/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$80.00 ➝ $74.00	+135.67%
10/7/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Schmidt Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
Get the Latest News and Ratings for IMCR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter.
9/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight
8/9/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$87.00 ➝ $89.00	+131.35%
8/9/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$92.00 ➝ $66.00	+74.05%
7/10/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$70.00 ➝ $66.00	+73.68%
5/9/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$63.00 ➝ $67.00	+12.25%
4/29/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Chang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/29/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$74.00	+26.58%
10/31/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$84.00	+91.87%
8/16/2023	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$84.00	+39.42%
8/11/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$85.00 ➝ $91.00	+48.89%
3/24/2023	Bryan, Garnier & Co Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$16.00	-66.22%
12/16/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$33.00 ➝ $80.00	+34.63%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:46 AM ET.

IMCR Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Immunocore is $69.18, with a high forecast of $100.00 and a low forecast of $24.00.
: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last twelve months. There is currently 1 sell rating, 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IMCR shares.
: According to analysts, Immunocore's stock has a predicted upside of 113.39% based on their 12-month stock forecasts.
: Over the previous 90 days, Immunocore's stock had 2 downgrades by analysts.
: Immunocore has been rated by research analysts at Cantor Fitzgerald, Guggenheim, HC Wainwright, Mizuho, Morgan Stanley, Needham & Company LLC, and UBS Group in the past 90 days.
: Analysts like Immunocore less than other "medical" companies. The consensus rating score for Immunocore is 2.62 while the average consensus rating score for "medical" companies is 2.80. Learn more on how IMCR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

I was wrong. Dead wrong. (Ad)

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

This page (NASDAQ:IMCR) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunocore (IMCR) Stock Forecast & Price Target